Adaptimmune Bullish On Meeting Endpoint For Soft Tissue Cancer Trial

Adaptimmune Therapeutics plc ADAP will report updated data from its SPEARHEAD-1 Phase 2 trial with afamitresgene autoleucel (afami-cel, ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) at the Connective Tissue Oncology Society annual meeting.
The Company says that the trial will meet its primary endpoint for efficacy, and the data will be used to support marketing application filing for afami-cel next year.
Fifty patients had received afami-cel with a median dose of 8.5 billion transduced SPEAR T-cells.
Per Independent Review, the overall response rate was 34% (16/47 patients with partial responses (PRs))
The overall response rate was 36% in patients with synovial sarcoma and 25% for patients with MRCLS. The disease control rate was 85%.
Thirty-three (66%) patients experienced adverse events of cytokine release syndrome (CRS), most of which were lower grades.
Eight (16%) patients experienced severe cytopenia at Week 4.
Related Link: Adaptimmune Shares Encouraging Data From Solid Tumor Trial.
Price Action: ADAP shares are down 7.35% at $4.79 during the market session on the last check Thursday.